KAS
PACB icon

Kestra Advisory Services’s Pacific Biosciences PACB Stock Holding History

Kestra Advisory Services’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$45.9K Sell
34,798
-60
-0.2% -$107 ﹤0.01% 3060
2025
Q4 		$65.2K Buy
34,858
+652
+2% +$1.25K ﹤0.01% 3769
2025
Q3 		$43.8K Buy
+34,206
New +$46.3K ﹤0.01% 2865

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Kestra Advisory Services's PACB Position: Q1 2026 in Review

Kestra Advisory Services reduced its Pacific Biosciences (PACB) stake by 0.17% in Q1 2026, selling an estimated $107 and leaving 34,798 shares worth $45.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3060.

Kestra Advisory Services first reported a position in PACB in Q3 2025 and has held it in 3 quarters since. The position peaked at $65.2K in Q4 2025. 229 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

  • Kestra Advisory Services held 34,798 shares of Pacific Biosciences worth $45.9K as of Q1 2026.
  • Kestra Advisory Services sold 60 Pacific Biosciences shares in Q1 2026, an estimated $107.
  • Pacific Biosciences made up ﹤0.01% of Kestra Advisory Services's portfolio in Q1 2026, its #3060 holding.
  • Kestra Advisory Services first reported a position in Pacific Biosciences in Q3 2025 and has held it in 3 quarters since.
  • Kestra Advisory Services's Pacific Biosciences position peaked at $65.2K in Q4 2025.
  • 229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on Kestra Advisory Services's 13F filing for Q1 2026, filed 30 Apr 2026.